Bafna Pharmaceuticals Limited (IN:BAFNAPH)
:BAFNAPH
Want to see IN:BAFNAPH full AI Analyst Report?
BAFNAPH Stock Chart & Stats
₹154.65
-₹1.34(-1.60%)
At close: 4:00 PM EST
₹154.65
-₹1.34(-1.60%)
Day’s Range― - ―
52-Week Range₹72.25 - ₹216.25
Previous CloseN/A
Volume2.58K
Average Volume (3M)1.19K
Market Cap
₹4.14B
Enterprise Value₹3.44B
Total Cash (Recent Filing)₹19.67M
Total Debt (Recent Filing)₹324.03M
Price to Earnings (P/E)35.3
Beta0.62
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.70
Shares Outstanding23,656,336
10 Day Avg. Volume1,123
30 Day Avg. Volume1,187
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.69
Price to Sales (P/S)1.72
P/FCF Ratio-19.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Resilient Generic Pharma Business ModelThe company manufactures finished-dosage generics across multiple therapeutic categories and serves domestic and export markets. That business model yields steady, recurring demand, manufacturing control and diversified revenue streams that support durable cash flows and market access over years.
Multi-year Revenue Scale GrowthSustained top-line expansion over several years indicates improving product adoption and distribution scale. Scale supports manufacturing utilization, bargaining power with suppliers and payors, and provides a platform to absorb R&D or regulatory spend, strengthening long-term competitiveness.
Reasonable Balance Sheet With Equity BaseA meaningful equity base and only moderate leverage provide financial flexibility and a buffer against shocks. This supports access to external financing if needed and underpins capacity to fund growth or regulatory compliance without immediate solvency pressure.
Bears Say
Persistent Negative Free Cash FlowNegative free cash flow across most years indicates the business consumes cash despite reported profits. That reduces internal funding for capex, working capital and acquisitions, raises reliance on external financing, and weakens resilience to market or regulatory shocks over the medium term.
Rising Debt TrendAn upward debt trajectory increases interest and refinancing risk, particularly given weak free cash flow. Higher leverage can constrain strategic flexibility, elevate covenant risks, and amplify earnings sensitivity to margin compression or adverse market shifts over the coming months.
Earnings And Margin VolatilitySubstantial margin swings and episodic profit rebounds suggest earnings quality is uneven and sensitive to product mix, pricing or cost pressures. This variability hampers long-term planning, makes cash flow forecasting harder, and raises execution risk for sustained margin recovery.
Bafna Pharmaceuticals Limited News
BAFNAPH FAQ
What was Bafna Pharmaceuticals Limited’s price range in the past 12 months?
Bafna Pharmaceuticals Limited lowest stock price was ₹72.25 and its highest was ₹216.25 in the past 12 months.
What is Bafna Pharmaceuticals Limited’s market cap?
Bafna Pharmaceuticals Limited’s market cap is ₹4.14B.
When is Bafna Pharmaceuticals Limited’s upcoming earnings report date?
Bafna Pharmaceuticals Limited’s upcoming earnings report date is Aug 07, 2026 which is in 54 days.
How were Bafna Pharmaceuticals Limited’s earnings last quarter?
Bafna Pharmaceuticals Limited released its earnings results on May 29, 2026. The company reported ₹1.16 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.16.
Is Bafna Pharmaceuticals Limited overvalued?
According to Wall Street analysts Bafna Pharmaceuticals Limited’s price is currently Overvalued.
Does Bafna Pharmaceuticals Limited pay dividends?
Bafna Pharmaceuticals Limited pays a Notavailable dividend of ₹0.6 which represents an annual dividend yield of N/A. See more information on Bafna Pharmaceuticals Limited dividends here
What is Bafna Pharmaceuticals Limited’s EPS estimate?
Bafna Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bafna Pharmaceuticals Limited have?
Bafna Pharmaceuticals Limited has 23,656,336 shares outstanding.
What happened to Bafna Pharmaceuticals Limited’s price movement after its last earnings report?
Bafna Pharmaceuticals Limited reported an EPS of ₹1.16 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.372%.
Which hedge fund is a major shareholder of Bafna Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BAFNAPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bafna Pharmaceuticals Limited
Bafna Pharmaceuticals Limited is an Indian company that specializes in the production and distribution of completed pharmaceutical drugs. Its product portfolio encompasses a variety of tablet forms, including those designed for delayed or extended release, as well as chewable and orally disintegrating options. In addition to its domestic presence in India, the firm also engages in the international export of its pharmaceutical goods. Founded in 1981, Bafna Pharmaceuticals Limited maintains its headquarters in Chennai, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Krebs Biochemicals & Industries Ltd.
―
Mangalam Drugs & Organics Ltd.
―